Brigatinib is this ALK inhibitor that’s mainly used to treat a type of lung cancer called NSCLC when it’s ALK-positive and has spread. It’s created to stop ALK signals from getting through. They have it in three doses, 30 mg, 90 mg, and the highest one, 180 mg, and they’re all in these coated tablets.
You usually start with 90 mg a day for the first week, then go up to 180 mg once a day after that. They usually come in bottles with 30 tablets in each one.
